Kyntra Bio director granted 7,000 stock options

Kyntra Bio director Jeffrey L. Edwards received a grant of stock options covering 7,000 shares of common stock.

Rhea-AI Filing Summary

Kyntra Bio director Jeffrey L. Edwards received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and were granted as a compensation award rather than a market purchase or sale.

The award vests in four equal quarterly installments measured from the grant date and expires on June 11, 2036. Following this grant, Edwards holds options for 7,000 shares directly, giving him equity-based incentive aligned with the company’s future performance.

Insider Trade Summary

Grant/Award: 7,000 shares

Grant/Award 1 txn

Insider EDWARDS JEFFREY L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 7,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

Key Figures

Options granted: 7,000 shares Exercise price: $7.13 per share Total options after grant: 7,000 shares +3 more

6 metrics

Options granted 7,000 shares Stock Option (Right to Buy) awarded to director

Exercise price $7.13 per share Conversion or exercise price of the stock options

Total options after grant 7,000 shares Total derivative shares following the transaction

Grant date June 12, 2026 Transaction date for the option award

Expiration date June 11, 2036 Option term end date if not exercised

Vesting schedule Four equal quarterly installments Measured from date of grant per footnote

Key Terms

Stock Option (Right to Buy), exercise price, vest in four equal quarterly installments, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 7.1300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in four equal quarterly installments financial

"The shares subject to the option shall vest in four equal quarterly installments"

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did KYNTRA BIO (KYNB) director Jeffrey L. Edwards report on this Form 4?

Jeffrey L. Edwards reported receiving a grant of stock options for 7,000 shares of Kyntra Bio common stock. These were awarded as director compensation, not bought on the open market, and provide potential future ownership if exercised.

What is the exercise price of the KYNTRA BIO (KYNB) options granted to Jeffrey L. Edwards?

The stock options granted to Jeffrey L. Edwards have an exercise price of $7.13 per share. This means he can buy Kyntra Bio common stock at $7.13 if he exercises the options after they vest and before expiration.

How many KYNTRA BIO (KYNB) shares are covered by Jeffrey L. Edwards’ new option grant?

The new option grant covers 7,000 shares of Kyntra Bio common stock. All 7,000 shares are subject to vesting requirements and must be exercised at the $7.13 per share exercise price to become actual share ownership.

When do Jeffrey L. Edwards’ KYNTRA BIO (KYNB) stock options vest?

The options granted to Jeffrey L. Edwards vest in four equal quarterly installments measured from the grant date. This staggered vesting schedule rewards continued board service over time rather than immediately providing fully vested options.

When do the KYNTRA BIO (KYNB) stock options granted to Jeffrey L. Edwards expire?

The stock options granted to Jeffrey L. Edwards expire on June 11, 2036. He must exercise any vested options before that expiration date; otherwise, the right to purchase the underlying Kyntra Bio shares lapses.

Did Jeffrey L. Edwards buy or sell KYNTRA BIO (KYNB) shares in the market?

No market buy or sell occurred; Edwards received a grant of stock options as compensation. The Form 4 shows an acquisition of derivative securities, not an open-market purchase or sale of Kyntra Bio common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 07:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDWARDS JEFFREY L

(Last) (First) (Middle)

C/O KYNTRA BIO, INC.

350 BAY STREET, SUITE 110, #6009

(Street)

SAN FRANCISCO CALIFORNIA 94133

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.13	06/12/2026		A		7,000		(1)	06/11/2036	Common Stock	7,000	$0	7,000	D

Explanation of Responses:

1. The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.

	/s/ John Alden, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)